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Abstract
Background: The use of comprehensive instruments for guideline appraisal is time-consuming and requires highly
qualified personnel. Since practicing physicians are generally busy, the rapid-assessment Mini-Checklist (MiChe) tool
was developed to help them evaluate the quality and utility of guidelines quickly. The aim of this study was to
validate the MiChe in comparison to the AGREE II instrument and to determine its reliability as a tool for guideline
appraisal.
Methods: Ten guidelines that are relevant to general practice and had been evaluated by 2 independent
reviewers using AGREE II were assessed by 12 GPs using the MiChe. The strength of the correlation between
average MiChe ratings and AGREE II total scores was estimated using Pearson’s correlation coefficient. Inter-
rater reliability for MiChe overall quality ratings and endorsements was determined using intra-class
correlations (ICC) and Kendall’s W for ordinal recommendations. To determine the GPs’ satisfaction with the
MiChe, mean scores for the ratings on five questions were computed using a six-point Likert scale.
Results: The study showed a high level of agreement between MiChe and AGREE II in the quality rating of
guidelines (Pearson’s r = 0.872; P < 0.001). Inter-rater-reliability for overall MiChe ratings (ICC = 0.755; P < 0.001)
and endorsements (Kendall’s W = 0.73; P < 0.001) were high. The mean time required for guideline assessment
was less than 15 min und user satisfaction was generally high.
Conclusions: The MiChe performed well in comparison to AGREE II and is suitable for the rapid evaluation of
guideline quality and utility in practice.
Trial registration: German Clinical Trials Register: DRKS00007480
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Background
Clinical practice guidelines are defined by the Institute
of Medicine as “statements that include recommen-
dations intended to optimize patient care that are
informed by a systematic review of evidence and an
assessment of the benefits and harms of alternative
care options” [1]. There is evidence to suggest that
rigorously developed guidelines have the power to
translate the complexity of scientific research
findings and other evidence into recommendations
for healthcare action [2–8]. To increase guideline
quality, several institutions [1, 9–23] have prepared
manuals, that attempt to define standards for guide-
line developers. At the same time, tools have been
developed to help potential guideline users to assess
guideline quality. The most commonly used inter-
national guideline appraisal tool is the AGREE II
Instrument [24], but its use is time consuming and
demands considerable skill on the part of the guide-
line appraiser.
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Graham 2000 identified and compared guideline
appraisal tools in a systematic review [25], which was
later updated by Vlayen in 2005 [26] and Siering in 2013
[27]. Siering identified 40 different appraisal tools that
vary considerably in terms of the number of quality
dimensions taken into account. In the opinion of the
authors, appraisal tools containing many quality di-
mensions may not represent the best choice in all
cases. Depending on the problem being addressed, a
tool containing a few well thought out questions may
well suffice.
To be effective, guidelines must be applied by
clinicians. An appraisal tool that is quick and easy to
use and assesses the most relevant quality dimensions
of a guideline would generally encourage their wider
use. We therefore developed and published a mini-
checklist (MiChe) for the rapid appraisal of the
usefulness and quality of a guideline for clinical prac-
titioners. Detailed information on the development
process is provided elsewhere [28]. However, the
development was based on a systematic search in
guideline directories and bibliographic databases for
guideline appraisal instruments. The assessment cri-
teria used in the retrieved instruments were identified,
and their importance to the development of an effect-
ive rapid assessment tool was judged by German
guideline experts. The key criteria for MiChe were
then selected on the basis of the most commonly
found criteria in the retrieved instruments and the
ratings from the expert survey.
Our primary objective was to validate the MiChe
vs. the AGREE II instrument and determine its reli-
ability for daily users in terms of ability to rapidly
assess the strengths and weaknesses of a guideline
and dependability of content.
Methods
Twelve general practitioners (GPs) were asked to use the
MiChe to assess 10 eligible guidelines that had already




a) Validate the overall quality rating of AGREE II as
the gold standard vs. the overall quality rating of the
MiChe.
b) Estimate the inter-rater reliability of the overall
quality rating assigned by different guideline
assessors using the MiChe.
Secondary outcomes relating to the MiChe alone:
a) Demonstrate the inter-rater reliability of
endorsement: willing to recommend this guideline
for use in practice (“yes”; “yes, with certain
reservations” or “no”).
b) Demonstrate user satisfaction to indicate whether
the MiChe would help raters decide whether to
use a specific guideline or not.
c) Feedback to improve the MiChe.
d) Time required for an assessment using MiChe.
Tertiary outcomes:
Evaluate the correlation between overall quality rat-
ing and endorsement of the MiChe vs. quality ratings
of individual items (domain 1 – 6) of AGREE II.
Participants
During a quality circle that took place in November
2014, a convenience sample of GPs working as resi-
dent doctors was recruited from the more than 100
accredited general practices that make up GP
Research Network Frankfurt (ForN) [29]. GPs with
experience of guideline development or appraisal, i.e.
members of guideline commissions or GPs in post-
graduate training were excluded. All participants
received 1.5-h of training on the basics of guideline
development and appraisal at the Institute of Ge-
neral Practice in Frankfurt. In addition, a sample
guideline was provided, along with instructions to
read and appraise the guideline using the MiChe.
Participants later received a folder with a printed
version of 10 guidelines and were asked to use the
MiChe to appraise them. Results were returned by
mail.
In the Federal State of Hesse, Germany, the code of
medical ethics allows formal ethical approval to be
waived upon request if the biomedical research to be
conducted on patients or healthy volunteers involves
no risky procedures and is not invasive. We contacted
the local ethics committee of Frankfurt University
Hospital, who informed us that ethical approval could
be waived. As we were not expecting ethical approval
to be required, participating GPs were only required
to provide their verbal consent before starting to re-
view the guidelines.
Guideline selection and guideline assessment tools
The selection process was initiated by choosing
guidelines already known to the study team and by
studying a list of 20 guidelines, sorted according to
their characteristics. Of these, 10 guidelines were se-
lected that covered subjects that are relevant to gen-
eral practice, had varying AGREE II quality levels,
varied in length and were written in either German or
English. Two independent reviewers with professional
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expertise in guideline appraisal from the Institute for
Quality and Efficiency in Health Care (IQWiG) first
assessed the guidelines using the AGREE II instru-
ment. These assessments served as the gold standard
for the validation [24].
The MiChe [28, 30] contains 8 key-criteria that focus
on important methodological features (quality of guide-
line creation, quality of reporting, quality of presenta-
tion, quality of evidence synthesis), as well as a 3-level
assessment scale (see Fig. 1).
Data management
The GPs had to complete 10 MiChes for the 10 dif-
ferent guidelines and a short questionnaire on their
personal characteristics and previous experience of
guidelines. To indicate whether the MiChe would
help raters to decide whether or not to use a guide-
line, 5 questions addressed user satisfaction (satisfac-
tion, frequency of future use, makes it easier to deal
with guidelines, influence of guideline recommenda-
tions on future daily practice use, comprehensibility) using
a six-point Likert scale from 1 – 6, with 1 indicating a
strong positive response. The average time required for as-
sessment was measured separately for each guideline and
GP. Suggestions for improvement and notes were docu-
mented in a free text field.
Ethics approval was not required, since no patients
were involved. The protocol for this validity and reliabil-




The strength of the correlation between the average
MiChe ratings of the guidelines and the AGREE II total
score were estimated using Pearson’s correlation coeffi-
cient. A correlation of more than 0.70 is considered de-
sirable. Additionally, correlations between the average
recommendation on the MiChe and the separate
AGREE II domains were calculated using Spearman’s
rank order correlation.
Inter-rater reliability
Inter-rater agreement for the various MiChe ratings of
the GPs was determined using intra-class correlations
(ICC) and Kendall’s W for ordinal recommendations for
endorsement (“yes”, “yes, with certain reservations”,
“no”). For both coefficients, we consider values over 0.75
as good, values between 0.40 and 0.75 as moderate, and
values below 0.40 as poor [31].
Evaluation of the mini checklist
To determine the GPs’ satisfaction with the MiChe,
mean scores for the ratings on the five questions
quoted in the data management section were
computed.
Determination of required sample size
The required sample size to estimate inter-rater
agreement can be determined by defining a specific
null hypothesis and a specific alternative hypothesis,
and selecting a desired type I and type II error rate
(α and β level) [32]. We chose to set ICC = 0.50 as
the lowest acceptable agreement for the null hypoth-
esis and an expected value of ICC = 0.75 for the alter-
native hypothesis. For α = 0.05 and β = 0.20, 10 GPs
would have to evaluate 14 guidelines. The 10 guide-
lines evaluated in our study would still yield a statis-
tical power between 60 % and 70 %, and, as the
guidelines are not sampled randomly but selected to
elicit high variation in the AGREE II and MiChe
ratings, it would probably be higher. This, in turn,
makes it more likely to statistically confirm high
inter-rater agreement.
Results
Characteristics of the GPs and the tested guidelines
Twelve GPs (6 female) participated in our study.
Their mean age was 53 (SD 7) years and mean pro-
fessional experience as a GP 19 (SD 7) years; 6 worked in
a joint practice and 7 in a rural area with less than
60,000 inhabitants. None of the participants had used
a guideline assessment tool before, but all 12 GPS
had previously used guidelines as a source of information
(Table 1).
The included guidelines were published between
2006 and 2013, and covered different areas of rele-
vance to general practice. Six guidelines were in Ger-
man and 4 in English. They differed in length from 4
to 278 pages. The overall quality of the guidelines as
assessed by AGREE II varied between 2 and 6 points
on the 7-point scale. Four of them received a recom-
mendation of “yes”, 4 of “yes, with certain reserva-
tions” and 2 were given a “no” recommendation. The
average MiChe overall quality score across the 12
GPs ranged from 2.4 (SD 1.0) to 6.7 (SD 0.7) for the
10 guidelines. Based on the MiChe assessment, 6
guidelines received a majority recommendation of
“yes”, 1 of “yes, with certain reservations” and 3 were
given a “no” recommendation by the majority of the
GPs. The total AGREE II score was lower than the
total MiChe score for 7 of the 10 guidelines [33–39]
and higher for the remaining 3 [40–42]. The DEGAM
guideline on heart failure [34] was ranked best overall by
both instruments and 2 guidelines [39, 42] were poorly
ranked by both assessment tools (Table 2).
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Methodological Guideline Quality – Mini-Checklist  
1. The guideline has been written in a generally comprehensible manner and its key recommendations are easy to 
identify. 
2. The guideline’s target audiences and scope of application were specified. 
3. The background, the objectives of the guideline, and the patients for whom the guideline is relevant were 
clearly described.  
4. The persons that developed the guideline are named, and their financial independence and any conflicts of 
interest are clearly documented.  
5. The search for evidence was systematic and the criteria used to select evidence were described.  
6. The guideline recommendations are unambiguous and the evidence they are based on is clearly presented. 
7. Different treatment options are presented that take account of potential benefits, side effects and risks.  
8. Clear information is provided on how up-to-date the guideline is and for how long this is expected to be the 
case.   
 YES  TO SOME EXTENT  NO 
 YES  TO SOME EXTENT  NO 
 YES  TO SOME EXTENT  NO 
 YES  TO SOME EXTENT  NO 
 YES  TO SOME EXTENT  NO 
 YES  TO SOME EXTENT  NO 
 YES  TO SOME EXTENT  NO 
 YES  TO SOME EXTENT  NO 
Overall assessment of the quality of the guideline based on above results: 
Very poor 
1 2 3 4 5 6 7
Very good
Would you recommend others use the guideline? 
Yes Yes, with certain reservations  No 
Fig. 1 Mini-Checklist (MiChe)
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Primary endpoints on validity and inter-rater reliability of
the overall quality rating
The average MiChe quality rating of the guidelines was
strongly related to the total AGREE II score (Pearson’s
r = 0.872; one-tailed P < 0.001), as were the recommen-
dations to use the guidelines (Spearman’s ρ = 0.909;
one-tailed P < 0.001). Both results indicate a high level
of validity in the MiChe ratings.
Inter-rater reliability for the overall MiChe quality rat-
ings of the 12 GPs was ICC = 0.755 (one-tailed P < 0.001;
95 % CI: 0.572 < ICC < 0.914), indicating good agree-
ment between raters.
Secondary endpoint for the assessment of the
mini-checklist
For the inter-rater reliability of willingness to recommend
the guidelines, or “endorsement” for use in practice,
Kendall’s W for ordinal ratings was 0.73 (P < 0.001),
also indicating good agreement between raters.
Concerning user satisfaction, the mean value for over-
all satisfaction with the MiChe was 1.7 (SD 0.65) on the
six-point Likert scale. As an indicator of future use, the
mean value for the MiChe was 2.8 (SD 0.75). The ques-
tion whether the use of MiChe makes it easier to deal
with guidelines resulted in a mean value of 2.0 (SD
0.85). For the question on possible influence on the fu-
ture implementation of guideline recommendations in
daily practice work, the mean value was 2.2 (SD 0.83).
For the question on the comprehensibility of the
MiChe, the mean value was 1.3 (SD 0.65). For further
details see Fig. 2a-e.
The 12 GPs required an average of 12.9 min (SD
9.2) for the MiChe assessment. The mean appraisal
time for each guideline ranged from 6.8 to 20.1 min
(Table 2).
Eight GPs provided feedback. They would have liked
to have a more differentiated assessment scale and
mentioned that questions 2 and 3 were rather similar in
content. Another suggestion was to add a test question
regarding the existence of a structured pocket-version
of the guideline for use in practice. Some GPs reckoned
that assessments may depend on the language in which
the guideline was written and some criticized the
questions for their focus on methodological and for-
mal aspects, as they felt this may influence a result
even when a recommendation was of proven efficacy.
It was further mentioned that the MiChe does not
assess the practical usefulness of a guideline on a
day-to-day basis.
Correlation between the domains of AGREE II
and the MiChe
The average overall quality rating of the 10 guidelines
using MiChe was highly correlated (Pearson’s correla-
tions between 0.74 and 0.87) with the expert ratings
in the AGREE II domains II - IV and VI. Correlations
for the domains I and V were not statistically signifi-
cant (Table 3). The pattern of correlations on the
level of recommendation with the individual AGREE
II domains is very similar. Details of the AGREE II
for assessment per domain are shown in Table 4 in
the Appendix.
Discussion
Guidelines have the potential to improve the quality and
safety of health care, but are often not used in clinical
practice. In order to be helpful, a guideline must be of
high methodological quality. The use of comprehensive
research-focused instruments such as AGREE II is time-
consuming and requires highly qualified personnel. Since
practicing physicians are generally very busy, a new
rapid-assessment tool (MiChe) was developed to help
them evaluate the quality and utility of a guideline
quickly and on their own.
This paper presents the results of a validation-
study for MiChe [28], as compared to the AGREE II
instrument [24]. Ten guidelines that are relevant to
general practice and reflect a spectrum of methodo-
logical quality ranging from low to high according to
an appraisal using the AGREE II instrument were in-
cluded and assessed using the MiChe by 12 GPs that
Table 1 Characteristics of participating general practitioners
Characteristics (N = 12)








General practitioner (GP) [%] 67




Years in practice [mean (SD)] 25 (7.0)
Years as GP [mean (SD)] 19 (7.3)
Guideline experience
Used guidelines as source of information [%] 100
Former usage of e.g. AGREE or German
equivalent instrument [%]
0a
a one participant declined to respond
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Table 2 Mean overall rating scores for AGREE II and the MiChe
Guideline AGREE II MiChe












DEGAM Leitlinie Nr. 9, Herzinsuffizienz [Guideline no. 9
cardiac failure]/Deutsche Gesellschaft für Allgemeinmedizin
und Familienmedizin (DEGAM 2006) [34]




Guideline for the Management of Acute Bronchitis/Alberta 2008/6/CDN/English Bronchitis 3 Yes, with
modifications
2.5 (1.20) Yes: 17 9.7
Yes, with certain
reservations: 33
Clinical Practice Guideline Working Group (ACPG 2008) [40] No: 50
Diabetes und Schwangerschaft [Diabetes and pregnancy]/









Suspected cancer in primary care: Guidelines for investigation,
referral and reducing ethnic disparities/New Zealand Guidelines
Group (NZGG 2009) [38]
2009/190/NZ/English Cancer 4 Yes, with
modifications




Guidelines for the practice of diabetes self-management
education/American Association of Diabetes Educators
(AADE 2010) [41]
2010/46/USA/English Diabetes 4 Yes, with
modifications




Nebennierenrinden-Insuffizienz [Suprarenal gland failure]/
Deutschen Gesellschaft für Endokrinologie; Gesellschaft für
Kinderheilkunde und Jugendmedizin (DGKJ 2010) [42]
2010/4/GER/German Suprarenal
gland failure




Leitlinie Management der frühen rheumatoiden Arthritis
[Guideline managment of early rheumatoid arthritis]/Deutsche
Gesellschaft für Rheumatologie (DGR 2011) [37]
2011/163/GER/German Rheumatoid
arthritis




Aszites, spontan bakterielle Peritonitis, hepatorenales Syndrom
[Ascites, spontaneous bacterial peritonitis, hepatorenal
syndrome]/Deutsche Gesellschaft für Verdauungs-
undStoffwechselkrankheiten (DGVS 2011) [33]

















Table 2 Mean overall rating scores for AGREE II and the MiChe (Continued)
Leitlinie Management der frühen rheumatoiden Arthritis
[Guideline managment of early rheumatoid arthritis]/
Deutsche Gesellschaft für Rheumatologie (DGR 2011) [37]
2011/163/GER/German Rheumatoid
arthritis




Fieber unklarer Genese [Fever of unknown origin]/Gesellschaft
für Kinder- und Jugendrheumatologie Deutschen Gesellschaft
für Kinder- und Jugendmedizin (DGKJ 2013) [39]




Assessment and Management of Foot Ulcers for People with
Diabetes/Registered Nurses’ Association of Ontario (RNAO 2013) [35]
2013/160/USA/English Diabetic foot
lesions


















were inexperienced in guideline appraisal. The study
showed a high level of agreement in the quality rat-
ing of guidelines between MiChe and AGREE II and
recommendations to use the guideline. In addition,
inter-rater-reliability for the overall MiChe quality
ratings and MiChe recommendation for use in prac-
tice were high. With high user satisfaction and a
mean time required for guideline assessment of less
than 15 min, the MiChe was shown to be suitable
for the rapid assessment of guideline quality and util-
ity in practice.
Although the study shows high validity and inter-
rater-reliability for the MiChe, it nevertheless has a
number of limitations. The validation of the MiChe
was performed using the AGREE II instrument as the
gold standard for guideline appraisal. AGREE II is the
most frequently used instrument for the assessment
Table 3 Correlation between mean AGREE II domain-scores and
MiChe overall quality rate/MiChe recommendation for use





for use in practice






Domain 3: Rigor of
development
0.87* 0.80*
Domain 4: Clarity of
presentation
0.74* 0.69*











1 2 3 4 5 6
1 = very high ; 6 = very low







1 2 3 4 5 6
1 = very frequently; 6 = not at all







1 2 3 4 5 6
1 = significantly;  6 = not at all







1 2 3 4 5 6
1 = very high; 6 = none
Influence on future use of guideline







1 2 3 4 5 6
1 = very high; 6 = very low




Fig. 2 User satisfaction with the Mini-Checklist - 5 queries (a Satisfaction with the MiChe; b Future use of MiChe; c Makes it easier to deal with
guidelines; d Influence on future use of guideline recommendations in daily practice; e Comprehensibility of the MiChe)
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of methodological guideline quality and has been
validated in several studies [43–46]. Nevertheless it
remains unclear whether all items and domains of
AGREE II contribute equally to the quality of a
guideline [25]. The results of our findings that the
same individual AGREE II items (II-IV, VI) correlated
with both average overall quality ratings and levels of
recommendation should not be over-interpreted. The
correlations were probably caused by chance, even
though it was an interesting result that for domain 3
in particular (rigor of development), the correlation
was very high. In addition, we clearly recognize that
the questions on the MiChe cannot be seen as inde-
pendent of the individual AGREE II items. Further
empirical studies are needed to find out which items
and quality dimensions are essential to the assessment
of guideline quality.
Unfortunately we didn’t measure the time it took to
assess the guidelines using the AGREE II instrument.
However, the AGREE II consortium recommends the
use of at least 2 and preferably 4 appraisers and con-
sists of 23 key items organized within 6 domains
followed by 2 global rating items. Therefore, we as-
sumed that it requires considerably more time and
personnel resources to apply than are typically available
to a GP.
Guideline appraisal instruments can be used to as-
sess whether a guideline has been developed in a
methodologically accurate and transparent way in ac-
cordance with international standards. Guidelines
containing adequate information on these topics will
therefore be judged to be of high (methodological)
quality. But this appraisal is made regardless of
whether all recommendations made in the guideline
are correct or not. Thus some guidelines of high
methodological quality may still contain individual rec-
ommendations that are not internally valid in terms of
content. Equally, a guideline of low methodological
quality may contain recommendations of high content
validity [26, 47, 48].
Although the GPs involved in this study were inexperi-
enced in guideline appraisal, they received short, basic
training on guideline development and assessment be-
fore using the MiChe. A comparison between trained
and untrained clinicians with regard to the usability and
reliability of the MiChe was not part of this investiga-
tion. In addition, convenience sampling of the partici-
pants limits generalizability of the results. To achieve
wider implementation, future research should assess
whether clinicians with no prior training come to the
same results as trained clinicians and apply random
sampling techniques. To date only the German language
version of the MiChe has been validated. It would be
useful to know to what extent the use of an English
translation of the MiChe would lead to corresponding
results.
A large number of manuals and instruments can be
used for guideline development and quality assessment.
A systematic review carried out by Siering et al in 2013
[27] identified a total of 40 different appraisal tools. In-
formation on quality and validity was only available for
11 of these 40 tools, while detailed information concern-
ing the validation process was reported for only 6.
Among these, AGREE II was the most extensively vali-
dated instrument [43–46]. In recent years, a number of
clinician-focused rapid assessment tools have been de-
veloped contemporaneously, and in addition to com-
prehensive research-focused instruments. Apart from
MiChe, these include the iCAHE Guideline Quality
Checklist [49], the Global Rating Scale (GRS) of the
AGREE Collaboration [50], and the surgeons’ checklist
by Coroneos et al. [51]. Of these, MiChe is the only in-
strument of this type that is available in German and is
thus more easily accessible for German speakers. It is
also the only tool that has been validated for use in gen-
eral practice. In 2014, Grimmer et al tested the validity,
inter-rater reliability and clinical utility of the iCAHE
Guideline Quality Checklist in comparison to the
AGREE II instrument [49]. In their study they found a
moderate to strong correlation between the iCAHE and
the AGREE II scores. A comparison of these four tools
was published by Semlitsch et al. in 2015 [30] and
showed that, although developed independently, they all
focus on a few, broad-based and very similar key ques-
tions. They can therefore only give a rudimentary im-
pression of the value of a guideline. They are not
intended to provide a comprehensive and detailed guide-
line appraisal, and include only a broad-based rating
system.
Conclusion
Physicians increasingly use guidelines to gain clinical
knowledge. To be dependable, these guidelines need
to be prepared using proper methods and to be of
sufficiently high quality. The MiChe is a validated
rapid-assessment instrument that allows busy physi-
cians to assess the methodical quality of guidelines
without the need for experts in guideline appraisal
and judge whether a guideline is applicable in patient
care or not. It thus increases the likelihood that
guideline recommendations will be used in practice
and contributes towards sustained improvement in patient
health care.
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